Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Therapeutic Index By Combination Of Adriamycin And Docetaxel Depends On Dosing Time In Mice.

M. Tabuchi, H. To, H. Sakaguchi, N. Goto, A. Takeuchi, S. Higuchi, S. Ohdo
Published 2005 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
Although the combination of adriamycin and docetaxel showed a better cure rate against metastatic breast cancer, severe myelosuppression and cardiotoxicity were dose-limiting factors. The purpose of this study was to establish a suitable dosing schedule, based on a chronopharmacologic approach, to relieve severe adverse effects. In experiment 1, adriamycin or docetaxel was injected i.p. at 2, 6, 10, 14, 18, or 22 hours after light onset (HALO) to estimate toxicities. In experiment 2, the dosing time dependency of toxicity and pharmacokinetics were assessed in the combination of adriamycin and docetaxel. In addition, G2-M phase in myelocyte cells was determined in nontreated mice. Adverse effects caused by adriamycin were shown to be the worst at 2 HALO and the best at 14 HALO. On the other hand, docetaxel-induced adverse effects were more severe at 14 HALO than at 2 HALO. In the combination study, the D(2)-A(1)4 group, in which docetaxel was administered at 2 HALO followed by adriamycin at 14 HALO, showed the most toxicity relief of all the treated groups. In the pharmacokinetic study, the dosing time dependency of toxicities was not related to the daily variation of pharmacokinetics of adriamycin and docetaxel. A significant 24-hour rhythm of G2-M phase distribution was found in myelocyte cells of nontreated mice. The daily variation of leukopenia caused by docetaxel corresponded to the 24-hour rhythm of G2-M phase distribution. These findings reveal that the therapeutic index of the combined chemotherapy can be improved by administering adriamycin and docetaxel at the time when the most adverse effects are relieved in each drug.
This paper references
chemotherapy for women with metastatic breast cancer
(2004)
Long-survival in responding patients with metastatic breast cancer treated with doxorubicin-docetaxel combination. A multicentre phase II trial.
R. Mattioli (2004)
10.1097/00000421-199312000-00007
Circadian-timed Combination Doxorubicin-cisplatin Chemotherapy for Advanced Endometrial Carcinoma: A Phase Ii Study of the Gynecologic Oncology Group
R. Barrett (1993)
Docetaxel in combination chemotherapy for metastatic breast cancer.
D. Khayat (1997)
10.1093/ANNONC/MDH107
A randomized phase II study of combination, alternating and sequential regimens of doxorubicin and docetaxel as first-line chemotherapy for women with metastatic breast cancer.
S. Cresta (2004)
In vitro evaluation of schedule-dependent interactions between docetaxel and doxorubicin against human breast and ovarian cancer cells.
S. Zeng (2000)
10.1211/0022357001777711
Time‐dependent Nephrotoxicity Associated with Daily Administration of Cisplatin in Mice
H. To (2000)
Lipid lowering: an important factor in preventing adriamycin-induced heart failure.
N. Iliskovic (1997)
Study of dose escalation and sequence switching of administration of the combination of docetaxel and doxorubicin in advanced breast cancer.
K. Itoh (2000)
Experimental chronotherapy of mouse mammary adenocarcinoma MA13/C with docetaxel and doxorubicin as single agents and in combination.
T. Granda (2001)
Synthetic adrenocorticotropin for optimizing murine circadian chronotolerance for adriamycin.
F. Levi (1980)
10.1634/THEONCOLOGIST.9-5-518
Carboplatin in combination therapy for metastatic breast cancer.
E. Perez (2004)
10.1126/SCIENCE.3883493
Circadian timing of cancer chemotherapy.
W. Hrushesky (1985)
10.1038/clpt.1993.69
Pharmacokinetics and pharmacodynamics of doxorubicin in patients with small cell lung cancer
S. Piscitelli (1993)
10.1016/S0959-8049(03)00601-4
Clinical outcome of breast cancer patients with liver metastases alone in the anthracycline-taxane era: a retrospective analysis of two prospective, randomised metastatic breast cancer trials.
G. Atalay (2003)
10.1200/JCO.2003.04.040
Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial.
J. Nabholtz (2003)
Nanomolar range docetaxel treatment sensitizes MCF-7 cells to chemotherapy induced apoptosis, induces G2M arrest and phosphorylates bcl-2.
G. J. Berchem (1999)
Docetaxel chronopharmacology in mice.
M. Tampellini (1998)
10.1211/002235703765951410
Dosing time dependency of doxorubicin‐induced cardiotoxicity and bone marrow toxicity in rats
H. To (2003)
10.1016/0041-008X(78)90268-5
Chronic cardiotoxicity of doxorubicin (adriamycin) in the rat: morphologic and biochemical investigations.
H. M. Olson (1978)
10.1081/CBI-100107520
CISPLATIN-INDUCED VOMITING DEPENDS ON CIRCADIAN TIMING
M. Kobayashi (2001)
10.1016/S0140-6736(97)03358-8
Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer
F. Lévi (1997)
10.1200/JCO.2003.11.071
Are anthracycline-taxane regimens the new standard of care in the treatment of metastatic breast cancer?
V. Valero (2003)
10.1200/JCO.1998.16.10.3439
Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women.
R. Fossati (1998)
10.1038/bjc.1993.146
Chemotherapy and survival in advanced breast cancer: the inclusion of doxorubicin in Cooper type regimens.
R. A'hern (1993)
Circadian bioperiodic response of mice bearing advanced L1210 leukemia to combination therapy with adriamycin and cyclophosphamide.
L. Scheving (1980)
10.1093/JNCI/84.23.1781
Phase I trial of Taxotere: five-day schedule.
R. Pazdur (1992)
Docetaxel chronopharmacology in mice Dosing-time dependency of adriamycin-induced cardiotoxicity and bone marrow toxicity in rats
M Tampellini (1998)
10.1016/S0959-8049(99)00282-8
Chronotherapy with 5-fluorouracil, folinic acid and carboplatin for metastatic colorectal cancer; an interesting therapeutic index in a phase II trial.
C. Focan (2000)
10.1056/NEJM199810013391407
Treatment of breast cancer.
G. Hortobagyi (1998)
Docetaxel and paclitaxel in breast cancer therapy: present status and future prospects.
G. D'Andrea (1997)
Dosing-time dependency of adriamycin-induced cardiotoxicity and bone marrow toxicity in rats
H To (2003)
Cancer Research Cancer Res
(2005)
A randomized phase II study of combination, alternating and sequential regimens of doxorubicin and docetaxel as first-line Dosing Time–Dependent Effects of Adriamycin/Docetaxel www.aacrjournals.org
S Cresta (2005)
Bcl2 is the guardian of microtubule integrity.
S. Haldar (1997)
10.1158/1078-0432.CCR-1000-03
Influence of Dosing Schedule on Toxicity and Antitumor Effects of a Combination of Adriamycin and Docetaxel in Mice
H. To (2004)
Chronopharmacologic optimization of docetaxel-doxorubicin combination in mice with P388 leukemia (Abstract 3885)
E Filipski (1999)
10.1016/J.EJCA.2004.01.011
Cardiac safety of trastuzumab in combination with epirubicin and cyclophosphamide in women with metastatic breast cancer: results of a phase I trial.
M. Untch (2004)



This paper is referenced by
10.1254/JPHS.12059FP
Chronopharmacology of mizoribine in collagen-induced arthritis rats.
Yuko Kanasaki (2012)
10.1016/j.bcp.2010.04.037
A toxicoproteomic study on cardioprotective effects of pre-administration of docetaxel in a mouse model of adriamycin-induced cardiotoxicity.
K. Ohyama (2010)
10.3329/BSMMUJ.V11I2.36780
Estimation of paracetamol in urine to assess the diurnal variation
M. Bhowmik (2018)
10.1186/s12885-016-2777-0
Influence of dosing times on cisplatin-induced peripheral neuropathy in rats
Y. Seto (2016)
10.1371/journal.pone.0102054
Chronopharmacodynamics and Chronopharmacokinetics of Pethidine in Mice
Chengliang Zhang (2014)
10.1248/YAKUSHI.126.415
[Construction of optimal combined chemotherapy of anti-tumor drugs based on chronotherapy].
H. To (2006)
27 Chronobiology of and Chronotherapy for Rheumatoid Arthritis
H. To (2012)
10.5649/JJPHCS.33.897
Optimization of Combination Chemotherapy with Anti-Tumor Drugs Based on Experimental Animal Study
H. To (2007)
10.1007/s10549-007-9667-8
Pre-administration of docetaxel protects against adriamycin-induced cardiotoxicity
H. Sakaguchi (2007)
10.1080/09291016.2013.787684
Murine chronotoxicity to pharmaceutical wastewater
D. Dridi (2014)
10.1211/jpp.61.10.0009
Therapeutic index of methotrexate depends on circadian cycling of tumour necrosis factor‐α in collagen‐induced arthritic rats and mice
H. To (2009)
10.1016/j.addr.2010.06.002
Chronotherapy and the molecular clock: Clinical implications in oncology.
P. Innominato (2010)
10.1254/JPHS.11029FP
Dosing time-dependency of the arthritis-inhibiting effect of tacrolimus in mice.
Kayo Obayashi (2011)
10.3109/07420528.2011.553017
Methotrexate Chronotherapy is Effective Against Rheumatoid Arthritis
H. To (2011)
10.1211/jpp.61.05.0010
Influence of dosing schedules on toxicity and antitumour effects of combined cisplatin and docetaxel treatment in mice
Ayumi Kodama (2009)
10.5772/21980
Chronobiology of and Chronotherapy for Rheumatoid Arthritis
H. To (2011)
10.1248/BPB.31.95
Chronopharmacologic cancer treatment with an angiogenic vessel-targeted liposomal drug.
K. Shimizu (2008)
Chronobiology of and Chronotherapy for Rheumatoid Arthritis Hideto
H. To (2018)
Semantic Scholar Logo Some data provided by SemanticScholar